Skip to main content

Guardant Health GuardantInform

Guardant Health has launched a clinical-genomic database service it calls GuardantInform, intended to help accelerate research and development of the next generation of cancer therapeutics. The platform offers biopharma partners de-identified longitudinal clinical information and genomic data collected from the Guardant360 liquid biopsy test, which the firm has performed on more than 100,000 samples to date.

Among potential applications, Guardant highlighted targeted drug development, clinical trial optimization, and post-marketing pharma studies. According to the company, recent data presented at the AACR virtual annual meeting further support the database's potential in these areas.